A Venture Capital firm specializing in technologies, financials and healthcare industries is backed by an investment and hospital management team with more than 100 years and 80 years respectively of combined professional experiences.
The firm invests in three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with the firm’s domestic and foreign hospital & medical network.
The firm does not have management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based VC Firm Focuses on Medtech and Digital Health Investment Opportunities That Are Synergistic With Firm’s Investment and Hospital Network
30 Jun- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Listen to the Podcast
Top Posts
- RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee
- Hot Investor Mandate: Strategic Corporate VC Focused on Early-Stage Therapeutics, Medical Devices, and Digital Health Across the Globe
- Hot Investor Mandate: Asia-Based Private Investment Firm Actively Looks for Cross-Border Deals in All Life Science and Healthcare Sectors
- Hot Investor Mandate: USA-Based VC Firm Seeks Life Science Tools Technologies Based in North America and Europe
- Hot Investor Mandate: VC Firm Invests Up to $5M in Medical Device Companies Based in North America, With a Preference for 510k Cardio and Single-Use Devices
- RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment
- Webinar to Fundraising Strategy: Preparing CEOs for RESI Europe and Beyond
- The Needle Issue #24
- What are Best Practices for Cap Table Management? Investors & Banks Weigh In
- New EU Webinar Series - From Discovery to Decision: Making Early-Stage Life Science Legible to Capital
Recent Posts
- RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee
- RESI Europe and European VC Coalition Seek to Boost EU Biotech Investment
- Webinar to Fundraising Strategy: Preparing CEOs for RESI Europe and Beyond
- The Needle Issue #24
- Hot Investor Mandate: VC Firm Invests Up to $5M in Medical Device Companies Based in North America, With a Preference for 510k Cardio and Single-Use Devices
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]





Leave a comment